DB18839InvestigationalProtein Based Therapies
Tidutamab is under investigation in clinical trial NCT04590781 (Safety and Efficacy of Xmab18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer).
- Also known as
- Anti-sstr2/cd3 monoclonal antibody xmab18087
- Code names
- XMAB-18087
Resolves to
Compound
What you can answer from here — as of April 23, 2025
Which companies are running trials of Tidutamab, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account